Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL)

Ticker PILL · Since 2017-11-15 · · Holdings as of Jul 31, 2026

Expense ratio
0.98%$98/yr per $10k
5-yr return
−12.6%annualized
1-yr return
+75.0%as of Dec 2025
Net assets
$20.7Mall share classes
Holdings
73

Bottom line

Is PILL a good fund? The bottom line

PILL is an actively managed leveraged & inverse ETF from Direxion.

It charges 0.98% — about $98 a year on every $10,000 invested, cheaper than 76% of leveraged & inverse funds we track.

It returned +75.0% over one year, −12.6% a year over five years (as of Dec 31, 2025, per its prospectus).

With $20.7 million in net assets and 73 holdings, its largest position is Goldman Financial (22.4%) and the top 10 make up 67.5% of the portfolio.

What stands out

  • Low cost: cheaper than 76% of leveraged & inverse peers

What to watch

  • Concentrated: top 10 holdings are 67.5% of assets
  • Small fund ($20.7 million) — small funds are likelier to close

Updated Nov 19, 2026

What PILL invests in

The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

"The Index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the Global Industry Classification Standard (GICS) pharmaceuticals sub-industry. To be eligible for inclusion in the Index, stocks must satisfy one of the following combined size and liquidity criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%; (2) have a float-adjusted market capitalization above $500 million with a float-adjusted liquidity ratio above 90%; or (3) have a float-adjusted market capitalization above $400 million with a float-adjusted…

From the fund's prospectus (filed Mar 3, 2026).

PILL performance

Fund calendar-year total returns, 2018–2025 2018: −19.6%; 2019: +18.2%; 2020: −0.3%; 2021: −37.2%; 2022: −43.1%; 2023: −12.7%; 2024: −6.9%; 2025: +75.0% −20% 2018 +18% 2019 −0% 2020 −37% 2021 −43% 2022 −13% 2023 −7% 2024 +75% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PILL+75.0%−12.6%—
Leveraged & Inverse median−7.7%−11.8%−13.5%

Source: Fund prospectus, as of Dec 31, 2025

Full PILL performance history →

What PILL costs

On a $10,000 investment, PILL's 0.98% expense ratio costs about $98 a year. The prospectus estimates $1,456 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full PILL fee table →

PILL top 10 holdings

#Holding% of fund
1Goldman Financial22.36%
2N/a16.36%
3Dreyfus8.14%
4N/a7.41%
5Crinetics Pharmaceuticals In CRNX2.77%
6Mbx Biosciences Inc MBX2.42%
7Ataibeckley Inc ATAI UQ2.16%
8Definium Therapeutics, Inc DFTX2.13%
9Goldman Sachs Liq Es Fd A2.03%
10Amylyx Pharmaceuticals Inc AMLX UW1.72%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 67.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to PILL

More funds like PILL →

PILL FAQ

What is the expense ratio of PILL?
PILL's expense ratio is 0.98%, which works out to about $98 a year for every $10,000 invested. The prospectus estimates total costs of $1,456 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PILL a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 76% of leveraged & inverse peers; concentrated: top 10 holdings are 67.5% of assets; small fund ($20.7 million) — small funds are likelier to close. This is general information, not personalized advice.
What does PILL hold?
PILL's largest holdings are Goldman Financial (22.4%), N/a (16.4%), Dreyfus (8.1%), N/a (7.4%), Crinetics Pharmaceuticals In (2.8%). It holds 73 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is PILL's 5-year return?
PILL returned −12.6% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages PILL?
PILL is offered by Direxion through Direxion Shares ETF Trust.